Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy
Jason I. Griffiths, Jinfeng Chen, Patrick A. Cosgrove, et al.
Nature Cancer (2021) Vol. 2, Iss. 6, pp. 658-671
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 28, pp. 3246-3256
Open Access | Times Cited: 429
Deciphering breast cancer: from biology to the clinic
Emma Nolan, Geoffrey J. Lindeman, Jane E. Visvader
Cell (2023) Vol. 186, Iss. 8, pp. 1708-1728
Open Access | Times Cited: 354
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors
Sanju Sinha, Rahulsimham Vegesna, Sumit Mukherjee, et al.
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 938-952
Open Access | Times Cited: 31
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
Cynthia L. Palmer, Britton Boras, Bernadette Pascual, et al.
Cancer Cell (2025) Vol. 43, Iss. 3, pp. 464-481.e14
Open Access | Times Cited: 3
Therapeutic vaccines for breast cancer: Has the time finally come?
Chiara Corti, Pier Paolo Maria Berton Giachetti, Alexander M.M. Eggermont, et al.
European Journal of Cancer (2021) Vol. 160, pp. 150-174
Open Access | Times Cited: 64
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
Fiona H. Zhou, Teesha Downton, Allegra Freelander, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 25
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancer
Chenlin Liu, Fan Dong, Jiahui Sun, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Emerging clinical applications of single-cell RNA sequencing in oncology
Emily Boxer, Nisan Feigin, Roi Tschernichovsky, et al.
Nature Reviews Clinical Oncology (2025)
Closed Access | Times Cited: 1
Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor
Mithila Sawant, Audrey Wilson, Dhivya Sridaran, et al.
Oncogene (2023) Vol. 42, Iss. 29, pp. 2263-2277
Open Access | Times Cited: 17
Cell facilitation promotes growth and survival under drug pressure in breast cancer
Rena Emond, Jason I. Griffiths, Vince Kornél Grolmusz, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Rei Kudo, Anton Safonov, Catherine Jones, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1919-1935.e9
Open Access | Times Cited: 6
Immunomodulatory effects of CDK4/6 inhibitors
Shumeng Zhang, Qiaomai Xu, Wenjia Sun, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 4, pp. 188912-188912
Closed Access | Times Cited: 16
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Antonio Marra, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104148-104148
Closed Access | Times Cited: 15
In Silico Investigations of Multi-Drug Adaptive Therapy Protocols
Daniel S. Thomas, Luis Cisneros, Alexander R.A. Anderson, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2699-2699
Open Access | Times Cited: 19
Working with Convex Responses: Antifragility from Finance to Oncology
Nassim Nicholas Taleb, Jeffrey West
Entropy (2023) Vol. 25, Iss. 2, pp. 343-343
Open Access | Times Cited: 13
The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness
Karla Andrade de Oliveira, Surojeet Sengupta, Anil Yadav, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 13
CDK4/6 Inhibitor Resistance in Hormone Receptor-Positive Metastatic Breast Cancer: Translational Research, Clinical Trials, and Future Directions
Jin Sun Lee, Hannah Hackbart, Xiaojiang Cui, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11791-11791
Open Access | Times Cited: 11
JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer
C. Elizabeth Caldon, Sarah Alexandrou, Christine Lee, et al.
Research Square (Research Square) (2025)
Open Access
Cellular interactions within the immune microenvironment underpins resistance to cell cycle inhibition in breast cancers
Jason I. Griffiths, Patrick A. Cosgrove, Eric F. Medina, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor
Ian F. Tannock, Qamar J. Khan, Tito Fojo
Journal of Clinical Oncology (2025)
Closed Access
Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Malinda T West, Shaun Goodyear, Evie Hobbs, et al.
The Oncologist (2023) Vol. 28, Iss. 8, pp. 682-690
Open Access | Times Cited: 10
Multi-omics analyses unravel DNA damage repair-related clusters in breast cancer with experimental validation
Peng Liu, Xinpei Deng, Huamao Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Personalized tumor combination therapy optimization using the single-cell transcriptome
Chen Tang, Shaliu Fu, Xuan Jin, et al.
Genome Medicine (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Genomic and immune heterogeneity of multiple synchronous lung adenocarcinoma at different developmental stages
Yue Zhao, Jian Gao, Jun Wang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top